Eli Lilly’s (LLY) Alzheimer’s Drug Is Rejected in Europe Over Safety Fears
A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...
European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
Eli Lilly's Alzheimer's drug rejected in Europe
The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...
EU regulator rejects Eli Lilly's Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on ...
Eli Lilly to seek re-examination by CHMP of opinion to not recommend donanemab
The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion that does not recommend Eli Lilly (LLY) and ...
Devdiscourse1d
EU Regulators Reject Eli Lilly's Alzheimer's Drug: A Risky Decision?
The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...
BioPharma Dive1d
Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
EU regulator declines approval for Eli Lilly’s new Alzheimer’s drug
The EU’s medicines regulator has declined to approve Eli Lilly’s new Alzheimer’s drug, deciding the risks of serious and potentially fatal side effects outweigh the benefits of slowing progression of ...
Eli Lilly Alzheimer’s Drug Kisunla Fails to Get EU Backing
(Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the ...